Clinical drug safety
Precision safety insights for clinical studies using LiquiPath™
The challenge
Drug safety monitoring is a major bottleneck in drug development
Current approaches are too slow, fragmented, and lack the sensitivity for early detection of organ injury. As a result, safety signals are detected too late, delaying development, increasing costs, and putting patients at risk.
30% of drugs fail during clinical studies due to unresolved toxicity
1 in 3 FDA-approved drugs are later linked to safety or toxicity issues
Drug-induced adverse events prevent life-saving therapies from reaching patients
Our solution
Real-time organ health
LiquiPath redefines how we can monitor drug safety. For the first time, a single blood sample can provide real-time insight into treatment response across multiple organs, moving beyond today’s single-organ tests.
Unmatched insights
Our multi-tissue monitoring approach enables early detection of subclinical toxicity before irreversible damage occurs. By combining rapid turnaround times with precise, repeatable monitoring, we aim to identify safety signals earlier, helping the right patients stay on treatment for longer.
-
LiquiPathTraditional approaches
-
Non-invasive, precision monitoring
-
Single sample multi-organ surveillance
-
Early detection
-
Cell-type specific insights
-
Integrated efficacy & safety
-
Patient stratification
-
Fast turnaround times
Join the revolution
Early access customers will have the opportunity to shape the capabilities of our organ health platform before general availability
Contact us to learn more about how we can improve your safety monitoring approach
Contact us